CME Test Questions: July 2013

1
CME TEST QUESTIONS: JULY 2013 Examination available at http://learn.sirweb.org/. To take the online JVIR CME tests, please log into the SIR Learning Center with your SIR user name and password. Nonmembers: If you do not already have an SIR username and password, please click on Create an Accountto gain access to the SIR Learning Center. Once in the Learning Center, click on the Publicationactivity type for a listing of all available JVIR CME Tests. Each test will be available online for 3 years from the month/date of publication. The CME questions in this issue are derived from the article Survival Outcomes and Prognostic Factors of Transcatheter Arterial Chemoembolization for Hepatic Neuroendocrine Metastasesby Hur et al. 1. Neuroendocrine tumors (NETs) most commonly metastasize to: a) The liver b) The spleen c) The axial skeletal system d) The brain 2. In this study, complete or partial response (RECIST) of hepatic metastasis from NETs follow- ing transcatheter arterial chemoembolization was observed in: a) o 10% of patients b) 20%30% of patients c) 40%70% of patients d) 4 70% of patients 3. In this study, the median overall survival for non- pancreatic NETs following chemoembolization was in the range of: a) 36 weeks b) 612 months c) 35 years d) 510 years 4. On a multivariate analysis, the authors concluded that all of the following were signicant prognostic factors for overall survival following chemoemboli- zation EXCEPT: a) Total hepatic tumor burden b) Total number of chemoembolizations c) Presence of enterobiliary communication d) Presence of extrahepatic metastasis 5. Following chemoembolization, the presence of an enterobiliary communication puts the patient at a signicantly higher risk for: a) Postembolization syndrome b) Encephalopathy c) Variceal hemorrhage d) Liver abscess

Transcript of CME Test Questions: July 2013

Page 1: CME Test Questions: July 2013

CME TEST QUESTIONS: JULY 20

13

Examination available at http://learn.sirweb.org/. To take the online JVIR CME tests, please log into the SIRLearning Center with your SIR user name and password. Nonmembers: If you do not already have an SIR usernameand password, please click on “Create an Account” to gain access to the SIR Learning Center. Once in the LearningCenter, click on the “Publication” activity type for a listing of all available JVIR CME Tests. Each test will beavailable online for 3 years from the month/date of publication.

The CME questions in this issue are derived from the article “Survival Outcomes and Prognostic Factors ofTranscatheter Arterial Chemoembolization for Hepatic Neuroendocrine Metastases” by Hur et al.

1.

Neuroendocrine tumors (NETs) most commonlymetastasize to:a) The liverb) The spleenc) The axial skeletal systemd) The brain

2.

In this study, complete or partial response(RECIST) of hepatic metastasis from NETs follow-ing transcatheter arterial chemoembolization wasobserved in:a) o 10% of patientsb) 20%–30% of patientsc) 40%–70% of patientsd) 4 70% of patients

3.

In this study, the median overall survival for non-pancreatic NETs following chemoembolization wasin the range of:a) 3–6 weeksb) 6–12 monthsc) 3–5 yearsd) 5–10 years

4.

On a multivariate analysis, the authors concludedthat all of the following were significant prognosticfactors for overall survival following chemoemboli-zation EXCEPT:a) Total hepatic tumor burdenb) Total number of chemoembolizationsc) Presence of enterobiliary communicationd) Presence of extrahepatic metastasis

5.

Following chemoembolization, the presence of anenterobiliary communication puts the patient at asignificantly higher risk for:a) Postembolization syndromeb) Encephalopathyc) Variceal hemorrhaged) Liver abscess